Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and more nuanced than headlines suggest. Whether this path is right for you...
Quick answer: Microdosing psychedelics means taking very small, sub-perceptual doses of substances such as psilocybin or LSD, usually on a repeated schedule rather than in a single full journey. While many people report benefits like improved mood and focus,...
Quick answer: A LSD For Anxiety randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation developed by MindMed, produced significant reductions in generalized anxiety disorder symptoms...
Quick answer: The FDA declined to approve MDMA-assisted therapy for PTSD, citing gaps in safety data, questions about how long the benefits last, and concerns about who was enrolled in the trials. The rejection letter is now public. It does not mean MDMA therapy is...
Quick answer: A peer-reviewed study published in npj Aging found that psilocybin extended lifespan and reduced markers of cellular aging in female mice, including lower oxidative stress and better-preserved telomeres. These are genuinely interesting findings. They are...
RFK Jr. psychedelic therapy support has brought significant new attention to substances like psilocybin, MDMA, and ibogaine as legitimate tools for mental health care. For seekers who have been quietly researching this space, the political shift is real but so is the...
